
==== Front
Int J Oncol
Int J Oncol
IJO
International Journal of Oncology
1019-6439
1791-2423
D.A. Spandidos

39219285
10.3892/ijo.2024.5682
ijo-65-04-05682
Review
FGFR-related phenotypic and functional profile of CAFs in prognostication of breast cancer (Review)
Solek Julia 1
Braun Marcin 1
Sadej Rafal 2
Romanska Hanna M. 1
1 Department of Pathology, Chair of Oncology, Medical University of Lodz, 92-213 Łodz, Poland;
2 Laboratory of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, 80-384 Gdansk, Poland
Correspondence to: Dr Hanna M. Romanska, Department of Pathology, Chair of Oncology, Medical University of Lodz, 251 Pomorska Street, 92-213 Łodz, Poland, E-mail: hanna.romanska@gmail.com
Professor Rafal Sadej, Laboratory of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, 1 Debinki Street, 80-384 Gdansk, Poland, E-mail: rafal.sadej@gumed.edu.pl
10 2024
26 8 2024
26 8 2024
65 4 9404 4 2024
31 7 2024
Copyright: © 2024 Solek et al.
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
While preclinical studies consistently implicate FGFR-signalling in breast cancer (BC) progression, clinical evidence fails to support these findings. It may be that the clinical significance of FGFR ought to be analysed in the context of the stroma, activating or repressing its function. The present review aimed to provide such a context by summarizing the existing data on the prognostic and/or predictive value of selected cancer-associated fibroblasts (CAFs)-related factors, that either directly or indirectly may affect FGFR-signalling. PubMed (https://pubmed.ncbi.nlm.nih.gov/) and Medline (https://www.nlm.nih.gov/medline/medline_home.html) databases were searched for the relevant literature related to the prognostic and/or predictive significance of: CAFs phenotypic markers (αSMA, S100A4/FSP-1, PDGFR, PDPN and FAP), CAFs-derived cognate FGFR ligands (FGF2, FGF5 and FGF17) or inducers of CAFs' paracrine activity (TGF-β1, HDGF, PDGF, CXCL8, CCL5, CCL2, IL-6, HH and EGF) both expressed in the tumour and circulating in the blood. A total of 68 articles were selected and thoroughly analysed. The findings consistently identified upregulation of αSMA, S100A4/FSP-1, PDGFR, PDPN, HDGF, PDGF, CXCL8, CCL5, CCL2, IL-6, HH and EGF as poor prognostic markers in BC, while evaluation of the prognostic value of the remaining markers varied between the studies. The data confirm an association of CAFs-specific features with BC prognosis, suggesting that both quantitative and qualitative profiling of the stroma might be required for an assessment of the true FGFR's clinical value.

Key words

FGFR
CAFs
biomarkers
secretome
BC
National Science CentreUMO-2020/39/B/NZ4/02696 The present study was supported by the National Science Centre (grant no. UMO-2020/39/B/NZ4/02696).
==== Body
pmc1. Introduction

Fibroblast growth factor (FGF) receptor (FGFR)-mediated interactions between tumour microenvironment (TME) and breast cancer (BC) cells in progression and response to therapy are well documented (1,2). While preclinical studies consistently implicate FGFR signalling in BC development, clinical evidence to support its pro-tumorigenic role is still missing (3,4). One of the possible reasons for the discordance between mechanistic and clinical findings as well as disappointing results of clinical trials with FGFR inhibitors in BC (5,6) may be an inability of in vitro models to truly represent an in vivo setting and biological complexity of the TME. As FGFR-pathway is regulated by TME-derived stimuli, the clinical value of FGFR in BC ought to be analysed in the context of the stromal component, activating or repressing its function, in particular, cancer-associated fibroblasts (CAFs), that either directly (cognate ligands; FGFs) or indirectly (various factors enhancing CAFs' paracrine activity), may affect FGFR signalling (7,8).

CAFs, the most abundant cellular component of the TME present a highly heterogenous population, whose remarkable phenotypic and functional diversity is due mostly to distinct cellular origins, such as resident fibroblasts, bone marrow-derived mesenchymal stem cells, pericytes, endothelial or cancer cell (9). Various factors produced by cancer cells, host immune or other stromal cells, for example tumour growth factor β (TGF-β), platelet-derived growth factor (PDGF), sonic hedgehog (HH), interleukin 6 (IL-6), and a wide array of chemokines (9-18), induce differentiation and activation of CAFs. CAFs participate in various aspects of carcinogenesis, interacting directly and/or indirectly with tumour cells as well as various components of TME including myeloid cells. They have been most extensively investigated in the context tumour immunosuppressive microenvironment and its potential clinical significance (19,20). In BC, CAFs have been shown to promote cancer cell proliferation, remodelling of the extracellular matrix (ECM), angiogenesis and metastasis as well as modulate immune responses and drug resistance (19). This suggests that the overall impact of CAFs on tumour progression, and hence disease prognosis, is determined by the spatio-temporal pattern of their distribution and activation. A series of excellent recent reviews discuss various aspects of CAFs' biology, their impact on progression and responsiveness to therapy in several solid tumours, including BC.

Unequivocal documentation of CAFs is notoriously difficult, as none of the available phenotypic markers are entirely specific or exclusive. Inherent plasticity between CAFs subtypes further conceals their true phenotypic identity (20-23). Most commonly, CAFs are being detected on the basis of their morphology, positivity for mesenchymal biomarkers, for example alpha-smooth muscle actin (αSMA), fibroblast-activating protein (FAP), fibroblast-specific protein (FSP/S100A4) and platelet-derived growth factor receptor-β (PDGFRβ) as well as lack of expression of lineages markers for epithelial, endothelial or hematopoietic cells (20,21,23). However, because of their dynamic interactions with the tumour and other TME components, not a single marker, but a panel of phenotypically- and functionally-related features, so-called 'a stromal signature', is better positioned to define CAFs with regards to patients' prognosis (24). And indeed, several molecular stromal signatures have already been shown to have a prognostic and predictive value, complementary to that of phenotypic markers of the BC epithelial compartment (25,26).

There is growing evidence to suggest that through their secretome, encompassing a range of biologically active molecules such as growth factors, chemokines and cytokines, CAFs influence the course of BC development (1,27). In particular, being a source of FGF ligands, they act as paracrine upstream regulators of FGFR likely to affect BC evolution and development of therapy resistance (1,28-31).

Based on the reported data, a panel of stroma-derived factors was selected, called henceforth an 'FGFR-related CAFs' profile', that enables identification of a subpopulation of CAFs [phenotypic markers: αSMA, S100A4/fibroblast-specific protein 1 (FSP-1), PDGFR, podoplanin (PDPN), FAP (20,21)], with characteristics indicative of their potential regulatory effect on the FGF/FGFR axis [factors inducing CAFs paracrine activity: transforming growth factor (TGF)-β1, HDGF, PDGF, CXCL8, C-C motif chemokine ligand (CCL) 5, CCL2, IL-6, HH and EGF (32,33) and 3 CAFs-derived cognate FGF ligands: FGF2, FGF5 and FGF17 (34-38)] (Table I).

In the present study, existing data on the prognostic and, where available, predictive significance of the individual components of the so designed 'CAFs' profile' were summarized. To the best of our knowledge this is the first attempt to define the traits of CAFs specifically relevant to the activity of FGFR. Such a profile may represent a 'missing link' in the translation between mechanistic and clinical studies, thus supporting an evaluation of the true value of FGFR in BC prognostication (Fig. 1 and Table II).

The data have been organized into distinct paragraphs based on the tissue of origin of specific marker/s, whether expressed in the tissue (including the cytosol) or circulating in the blood (a substantial and easily accessible portion of the CAFs secretome). Details regarding the literature search, including a flowchart, are provided in Fig. 2.

2. Tissue proteins

Phenotypic markers αSMA

αSMA, a general marker of mesenchymal cells, is the most reliable marker of CAFs with a myofibroblast morphology (39). Alpha SMA can exist in a globular (G-actin) or filamentous (F-actin) form. The incorporation of αSMA into stress fibres, associated with the transition between G and F actin states, enhances the contractile properties of CAFs as well as the tension of the surrounding ECM (30). Via a mechanical feedback loop, αSMA-containing stress fibres participate in multiple cellular functions, ranging from the maintenance of cell shape and polarity to endosome dynamics and secretory pathways (39,40). Phenotypic transition into myofibroblasts and acquisition of the contractile features is one of the central traits of the activated stroma. It can be induced through several mechanisms, including auto- and paracrine stimulation by growth factors or cytokines (41). Activated myofibroblasts, in turn, secrete a number of soluble modulators, which contribute to ECM remodelling and, in cancer, promote invasiveness (39).

In BC, overexpression of αSMA in the stroma is consistently shown to be associated with unfavourable prognosis-an increased risk of metastases, shorter overall survival (OS) and disease-free survival (DFS) (28,42-47). Upregulation of αSMA was found to correlate with tumour high grade and positive nodal status (44,47,48). In human epidermal growth factor receptor 2 (HER2)-enriched BC, co-expression of αSMA, FGF5 and FGFR2, associated with upregulated c-Src, correlated with poor response to treatment (28), implicating the CAF (αSMA+)-FGF5-FGFR2-c-Src axis in development of resistance to HER2-targeted therapies. This was further supported by a demonstration of a link between αSMA overexpression in the stromal compartment and resistance to trastuzumab in patients with BC (45).

S100A4/FSP-1

S100A4 protein or FSP-1, localized in the cytoplasm and/or nucleus, is involved in the regulation of a number of cellular processes including cell cycle progression and differentiation. S100A4 is a polypeptide with two calcium-binding motifs, known to regulate, in a calcium-dependent manner, various cytoplasmic proteins, including the cytoskeletal components. The structural conformation of S100A4 upon calcium binding facilitates its interaction with RAGE on fibroblasts, activating intracellular signalling cascades such as the MAPK/ERK pathway (49). Furthermore, being secreted to the TME by activated stromal cells such as fibroblasts and immune cells, S100A4 supports growth factors release and angiogenesis, thus promoting tumour progression and metastasis (50). In macrophages, S100A4 binds to several intracellular proteins, which through the changes in cytoskeletal dynamics, promotes their recruitment to the tumour vicinity. In addition, S100A4 contributes to the pro-tumour macrophage polarization (51).

S100A4+ CAFs derive from adipocytes, post-epithelialmesenchymal transition (EMT) cancer cells or mesenchymal stem cells (52). S100A4+ CAFs play a tumour-protecting role in immune surveillance. In S100A4-deficient mice, mammary tumours do not metastasize (52). Furthermore, through secretion of vascular endothelial growth factor and tenascin C, S100A4+ CAFs participate in setting-up a pre-metastatic niche in the lung (53).

In patients with BC, S100A4 is an unfavourable prognostic factor and its upregulation correlates with tumour high grade and shorter OS (47,54-58). S100A4 expression varies between BC molecular subtypes and histologic features of the stroma (59). Upregulation of S100A4 in stromal cells was found to be associated with estrogen receptor (ER)-negativity and nodal metastases (54,56).

PDGFRα/β

PDGFR plays a critical role in tissue remodelling, scarring and fibrosis (60). It exists in two isoforms (PDGFRα and PDGFRβ) and is expressed in normal fibroblasts, pericytes, vascular smooth muscle cells, myocardiocytes and CAFs (21,61). Both PDGFRα and PDGFRβ are receptor tyrosine kinases with an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular tyrosine kinase domain. Binding of PDGF ligands to PDGFRα/β expressed on CAFs, induces receptor dimerization, autophosphorylation and its subsequent activation. This promotes secretion of collagen and other ECM components, that by enhancing the formation of the fibrotic stroma, support tumour development (30). PDGFR-mediated signalling induces transformation of pericytes into CAFs with enhanced secretory and inflammatory features (61,62). In particular, through FGF2 and FGF7, PDGFR+ CAFs promote neo-angiogenesis and cancer cell proliferation (63).

In BC, stromal PDGRFβ overexpression is associated with unfavourable clinicopathological characteristics such as high histological grade, larger tumour size (T), ER-negativity, upregulated HER2, as well as shorter DFS, recurrence-free survival (RFS) and OS (64-66). Expression of stromal PDGRβ was found prognostically significant particularly in tumours from premenopausal patients (67). Furthermore, randomized clinical studies of two BC cohorts identified stromal PDGFRβ as a marker of a therapeutic benefit of tamoxifen in early BC (65).

PDPN

PDPN, a mucin-type glycoprotein, promotes cancer cell migration and invasiveness and is expressed on fibroblasts, macrophages and tumour cells (20). PDPN is a transmembrane mucin-type glycoprotein with an extracellular domain rich in O-glycosylation sites. The single transmembrane helix anchors PDPN in the cell membrane and plays a role in transmitting signals from the extracellular environment to the intracellular activation of the RhoA/ROCK signalling pathway, which is involved in cytoskeletal dynamics, cell contractility and motility (68). Several studies demonstrated a positive association between increased levels of stromal PDPN, tumour grade, size (T), nodal status, ER- and progesterone receptor (PR)-negativity as well as shorter DFS and OS (47,52,69-73). Friedman et al (52) showed that, together with S100A4, PDPN may be instrumental in identification of CAF subpopulations, the ratio of which, having clinical implications across BC subtypes, is particularly correlated with BRCA mutations in triple-negative BC (TNBC). It was also demonstrated that the phenotypic composition of CAF population tends to fluctuate over time of cancer development. This supports the concept of CAFs' plasticity, as a key trait of a dynamic TME, co-evolving with the tumour, to nurture and provide a permissive microenvironment for its continuous growth (52).

FAP

FAP is a transmembrane serine protease with both dipeptidyl peptidase and endopeptidase activities. FAP's proteolytic activity allows it to degrade components of the ECM, such as gelatin, collagen and fibronectin. By ECM lysis, FAP generates bioactive fragments that can activate pro-tumorigenic signalling pathways in CAFs (74). FAP is a surface marker of activated fibroblasts in >90% of cancers (21). FAP-expressing CAFs are involved in various cancer-related processes, for example ECM-remodelling, but their key pro-tumorigenic role is ascribed to an impact on immune cell polarization and development of immunosuppressive TME (21). A number of FAP+ CAF-derived soluble effector molecules, such as stromal-derived factor 1 and CCL2, have been implicated in creation of an environment facilitating tumour development (75). In particular, FAP+ CAF-mediated activation of the uPAR-FAK-c-Src-JAK2-STAT3-CCL2 cascade enables recruitment of circulating myeloid-derived stem cells expressing CCR2, a cognate CCL2 receptor (21). Lo et al (76) demonstrated a correlation between FAP overexpression in CAFs and regulatory T cell-dependent immunosuppression. Accordingly, in BC, increased FAP+ CAFs were associated with features of poor prognosis, such as distant metastases and decreased RFS (77-79). By contrast, Ariga et al (78) has found high density of FAP+ CAFs prognostic of a longer OS and DFS (78), suggesting that FAP overexpression may also be related to extensive tissue remodelling and ECM turnover.

Activating factors

TGF-β1

The TGF-β, a large family of structurally related cytokines and growth factors, are involved in a vast number of cellular processes in development and homoeostasis of most human tissues. TGF-β1, in particular, a key regulator of the synthesis and expression of collagen, elastin and MMPs, acts through the canonical Smad-dependent and non-Smad pathways, that involve a number of receptors and interacting networks, and is strongly implicated in the pathogenesis of fibrosis (80,81). The major targets of TGF-β1 are fibroblasts, but other cell types, including macrophages, epithelial and vascular cells are also affected. In tumours, expressed at high level, TGF-β1 mediates EMT, promotes angiogenesis, and together with IL-1β, induces expression of FAP in fibroblasts (20). It is widely acknowledged, that an overall outcome of TGF-β1 activity depends on a type of a cell and its microenvironment. TGF-β1 was demonstrated to significantly affect both the fibroblast-myofibroblast transition and the rate of invasion (82). Koumoundourou et al (83) has also shown that downregulation of TGF-β1 in BC tissue was a marker of poor prognosis and recurrence. Using immunohistochemistry for TGF-β1, pSmad2/3 and Smad4, the authors demonstrated an inverse association between TGF-β1 and PR, as well as between Smad4 and ER, but not with any other clinicopathological features. Interestingly, although neither TGF-β1 nor pSmad2/3 were related to ER, loss of pSmad2/3 expression was prognostic of a shorter DFS in all patients, including those with ER-positive BC (83). Tissue expression of TGF-β1 and survivin was evaluated in BC samples by Liu et al (84), who found that, although none of them, separately, had an independent prognostic value, increased TGF-β1/survivin co-expression was associated with shorter OS and PFS in patients with TNBC (84).

HDGF

Heparin binding growth factor or hepatoma-derived growth factor (HDGF) shares homology with the high mobility group 1 protein and was first purified from a human hepatoma-derived cell line (85). Widely expressed in normal tissues, HDGF promotes proliferation of various cells, including fibroblasts, as both a DNA-binding nuclear factor and a secreted protein via a receptor-mediated pathway (86). In BC, Chen et al (87) demonstrated that strong expression of nuclear HDGF was associated with high tumour grade, high stage, high proliferation index (Ki-67 index >20%), lymph node metastases and shorter RFS. This was confirmed by Qiu et al (88), who reported a negative correlation between high expression of HDGF and DFS.

PDGF

PDGF is a growth factor that is secreted by cancer cells and induces activation of fibroblasts (89). There are five PDGF isoforms (A-D) but only PDGF-A and -B can form functional heterodimers, that stimulate their cognate receptors (90). In most tumours, populations of PDGF-expressing cancer cells are markedly denser than those positive for PDGFR, which indicates that PDFG plays a role as a mediator of paracrine activity of cancer cells towards the neighbouring stroma (90). The primary effect of PDGF on fibroblasts is their recruitment and stimulation of proliferation with, unlike TGF-β, no influence on the phenotypic switch into myofibroblasts (90). In BC, high expression of PDGF (AA and BB) was found to be correlated with high grade, high Ki67, young age (<50 years), tumour size, triple negativity and shorter DFS (91). Moreover, confirmed to be associated with poor prognosis in stage IV BC, PDGF (AA, BB, CC) was also shown to be predictive of a low response rate to chemotherapy (92).

Cytokines

The role of CAFs in orchestration of inflammation in immune TME is well recognized (62). Both target and source of a number of immune-modulatory and chemo-attractive mediators such as Chemokine (C-X-C motif) ligand 8 (CXCL8), CCL5, CCL2 and IL-6, CAFs participate in the recruitment of suppressive myeloid and regulatory T cells, polarization of M2 macrophages, suppression of cytotoxic lymphocytes and dendritic cells, that contribute to the modulation of TME towards tumour-promoting immunosuppressive environment (62,93).

CXCL8, CCL2 and CCL5, essential components of the tumour-stroma-inflammatory network, are associated with aggressive BC phenotype and increased risk of recurrence. Produced mostly by macrophages, these pro-inflammatory chemokines attract and activate resident immune cells (93), induce EMT (94), promote tumour metastasis (95) as well as modify tumour response to therapy (96). Higher levels of these three chemokines were shown to be associated predominantly with basal BC (93). Several studies have demonstrated an association between high expression of CCL2, high grade, lymph node metastases and HER2-negativity as well as shorter DFS and RFS (97,98). CCL5 was analysed by Yamaguchi et al (99), who found that stromal CCL5 was negatively associated with tumour size, as well as ER and PR expression. CCL5 levels significantly correlated with the aggressive phenotype and this was noted particularly in the CCR3-positive tumours (99). Moreover, in another study, expression of CCL5 was prognostic of shortened RFS, suggesting that CCL5 promotes BC progression and contributes to the worse disease outcome (100).

Hedgehog (HH)

The HH-signalling pathway plays a fundamental role in embryonic development of various organs and its dysregulation has been associated with several malignancies. In mammary gland, overactivation of HH-signalling has been suggested to stimulate self-renewal of normal and tumorigenic stem cells, thus promoting BC formation (101). However, prognostic and predictive value of HH pathway in BC still remains largely understudied. In a single study comprising 36 patients with TNBC, activation of HH combined with Wnt pathway identified patients at risk for early recurrence (102).

Cognate ligands-FGFs

FGFs are a family of signalling proteins, which in humans comprises 23 members, with paracrine (FGF1-10, FGF 16-18, FGF 20 and FGF22) or endocrine (FGF19, FGF21 and FGF23) mode of action. FGFs bind with different affinity to one or several of the four transmembrane FGF receptors (FGFR1-4) (103), activation of which, through the Ras-dependent MAPK, PI3K/AKT or STATs-dependent pathways, influences cell proliferation, differentiation and survival (Fig. 1) (104). Cellular responses induced by FGF/FGFR vary between biological contexts, which are determined by a number of factors, including cell type-specific adaptor molecules, signal transduction enhancers, transcription factors and co-activators, as well as interacting other signalling networks (34). Whereas translational significance of FGFRs' alterations in human cancer is being analysed by numerous research groups, albeit with conflicting results, available data on the clinical value of their ligands (FGFs) in BC are scarce, often inconclusive, and restricted only to: FGF2, FGF5 and FGF17. For example, while downregulation of FGF2 was found a marker of poor prognosis (105), its upregulation was associated with both shorter and longer RFS and OS (34,106-108). In a study by Colomer et al (105), downregulation of FGF2 was associated with longer OS and RFS; whereas Granato et al (109) reported that an association with survival parameters was not significant. Moreover, although upregulation of FGF2 correlated with small tumour size and decreased incidence of nodal metastases, it was inconsistently (both low and high) linked to tumour grade (106,107,110,111). Predictive value of FGF2 was reported by Shee et al (34), who demonstrated that its upregulation in ER+ BC was significantly predictive of anti-estrogen resistance and shorter RFS and OS. Upregulation of FGF5 was found to be associated with shorter OS and RFS (28). The only existing study of a prognostic value of FGF17 in BC demonstrated that its upregulation inversely correlated with tumour grade and nodal status (112).

3. Circulating proteins

aSMA, FAP, PDGFR, S100A4/FSP-1, PDPN, TGF-β1, IL-6

In most studies, increased serum (or plasma) level of aSMA, FAP, PDGFR, S100A4/FSP-1, PDPN, TGF-β1, IL-6 markers have been found to be linked to unfavorable disease indicators such as high grade, metastases and shorter OS (41,92,113-120).

By contrast, for TGF-b1 and IL-6, several studies documented their association with a good disease outcome. For example, Panis et al (121), showed that an early presentation of TNBC (<45 years of age) was associated with high levels of circulating TGF-β1, while in metastatic BC, TGF-β1 plasma concentration was lower than in non-metastatic disease. In a 40-month follow-up, women with low TGF-β1 levels (<20 pg/ml) were shown to have a tendency for a reduced OS and doxorubicin induced decrease in TGF-β1 concentration, promptly after drug infusion. Interestingly, levels of plasma TGF-β1 were not affected by surgical removal of the primary tumour and did not differ between patients with responsive and resistant disease (121). Milovanović et al (122) has found serum concentration of IL-6 as the independent prognostic factor of a good disease outcome.

The discrepancies between the studies are, at least partially, due to the well documented pleiotropy of both cytokines that, via either proor anti-inflammatory activity, may differently affect tumour progression.

CXCL8

Low level of serum CXCL8 was associated with higher pathological complete response of patients with TNBC in response to neoadjuvant chemotherapy (123).

Cytokine clusters

In an attempt to identify the cluster/s that would support the prognostic significance of longitudinal serum cytokine analysis, Paccagnella et al (124) have recently shown in patients with BC treated with eribulin that, after four courses of therapy, low levels of TGF-β, IL-4, IL-6, IL-8, IL-10, CCL-2 and CCL-4 (out of 18 cytokines evaluated) were associated with the best patient survival. This novel approach to design a kind of a prognostic 'serum signature', if validated, may prove very valuable in decision making related to the type and time course of applied therapy (124).

EGF

Known as the main ligand of the epidermal growth factor (EGF) receptor, a dominant oncogenic driver in numerous cancers, EGF plays also an important role in fibroblast differentiation and activation. Signalling from EGF downregulates Rho-GTP levels, which gives permissive signals for Rac1 activation and fibroblast polarization (125). This leads to fibroblast transformation into myofibroblasts which, together with growth-promoting action of TGF-β1, reciprocally promotes cancer cell invasion (125). However, at the clinical level, there is no evidence to demonstrate any translation value of stromal EGF in BC. Results of the only existing study evaluating EGF plasma level have demonstrated no significant associations with clinicopathological features or disease prognosis (126).

FGF2

The data on FGF2 showed that in a parallel evaluation in the serum and tissue, there was no correlation between its tumour expression and the corresponding serum level (105).

In summary, although determination of biomarkers obtainable by liquid biopsy appears to be very attractive for minimally invasive and inexpensive diagnosis and prognostication, the level of a secreted and/or shredded protein in the plasma, being not cell- or tissue-specific, does not faithfully reflect the expression in the analysed organ, and hence its role in the mechanisms of disease development. This implies that a more complex approach combining evaluation of a panel of both serum and histological biomarkers with imaging-based metrics may provide a more efficient tool for clinical practice.

4. Conclusion and perspectives

Available evidence clearly demonstrates that CAFs contain a valuable prognostic information in BC. While presented studies of single markers (for example αSMA, S100A4, PDGFR or PDPN) identify promising candidates, analyses combining several stromal, either CAFs-specific or CAF-derived features (for example S100A4/PDPN (52), αSMA/FGF5 (28), or PDGFR/FGF2/FGF7 (63) reveal the traits of clinically more significant implications. This indicates that comprehensive analyses of CAFs in relation to other components of the stroma might improve an assessment of CAFs involvement in the tumorigenic process and their value as prognostic and predictive biomarkers.

CAFs are not currently used in routine histopathological practice. The challenge is to design biologically meaningful signatures that would capture essential molecular profiles and could be exploited in prognostication. Given CAFs' heterogeneity, plasticity and an intricate cross-talk with other TEM components, it appears that this could be achieved by profiling the chosen (for example micro-dissected) area of the stroma towards carefully selected panel of makers relevant to specific aspects of BC biology. In particular, the proposed 'FGFR-related stromal profile of CAFs' might provide (after a necessary further clinical validation) the context for an assessment of the true FGFR's clinical value as well as the criteria for further classification of patients with BC for the FGFR-targeted therapy.

Acknowledgments

Not applicable.

Availability of data and materials

Not applicable.

Authors' contributions

JS designed the framework, performed the literature search, prepared the figure and the tables, and wrote the manuscript. MB supervised the research and selection of the literature. RS provided substantive support and critical review. HMR provided the concept and edited the manuscript. All authors have read and approved the final version of the manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

BC breast cancer

CAFs cancer-associated fibroblasts

DFS disease-free survival

ER estrogen receptor

FGF fibroblast growth factor

FGFR fibroblast growth factor receptor

HER2 human epidermal growth factor receptor 2

OS overall survival

PR progesterone receptor

RFS recurrence-free survival

TME tumour microenvironment

Figure 1 CAF subpopulations and factors inducing their paracrine activity. CAFs, originating from different cellular sources, represent a highly heterogenous population. Activated by various tumor microenvironment-secreted factors (included in Table I) are the main source of FGFRs' cognate ligands, FGFs. Activation of FGFR signalling, through various downstream pathways, including Ras dependent MAPK, PI3K/AKT or STATs, influences cellular proliferation, differentiation and drug resistance. CAF, cancer-associated fibroblast; FGFR, fibroblast growth factor receptor; PDGFR, platelet-derived growth factor receptor.

Figure 2 Flow chart of the literature search. PubMed and Medline databases were searched for the literature related to breast cancer and the prognostic and/or predictive significance of: CAFs phenotypic markers (αSMA/ACTA2, S100A4/FSP-1, PDGFR, PDPN and FAP), CAFs-derived cognate FGFR ligands (FGF2, FGF5 and FGF17) or inducers of CAFs paracrine activity (TGF-β1, HDGF, PDGF, CXCL8, CCL5, CCL2, IL-6, HH and EGF). Following exclusion criteria including pre-clinical (in vitro or animal) study and type of publication (review, case report), 68 out 1024 originally retrieved English language articles were finally selected and analysed. CAF, cancer-associated fibroblast; PDGFR, platelet-derived growth factor receptor; PDPN, podoplanin; FAP, fibroblast activating protein; HDGF, heparin binding growth factor; HH, sonic hedgehog; EFG, epidermal growth factor; CXCL, chemokine (C-X-C motif) ligand; CCL, C-C motif chemokine ligand; IL-6, interleukin 6.

Table I Components of the 'FGFR-related CAFs' profile'.

Phenotypic markers of CAFs	αSMA/ACTA2, S100A4/FSP-1, PDGFR, PDPN, FAP	
Factors activating CAFs	TGF-β1, HDGF, PDGF, CXCL8, CCL2, CCL5, IL-6, HH, EGF	
CAFs-secreted cognate ligands	bFGF (FGF2), FGF5, FGF17	
CAF, cancer-associated fibroblast; αSMA/ACTA2, alfa smooth muscle actin; S100A4/FSP-1, fibroblast specific protein; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; PDPN, podoplanin; FAP, fibroblast activating protein; TGF-β, tumour growth factor β1; HDGF, heparin binding growth factor; CXCL, chemokine (C-X-C motif) ligand; CCL, C-C motif chemokine ligand; IL-6, interleukin 6; HH, sonic hedgehog; EFG, epidermal growth factor; FGF, fibroblast growth factor.

Table II Reported associations between components of FGFR-related CAFs' profile, clinicopathological and prognostic variables.

			Marker		Correlation with clinicopathological values		Correlation with					
		First author/s, year	CAFs' phenotypic markers	Expression of stromal marker	Grade	Tumour size (T)	Nodal metastasis (N)	Molecular subtype	Prognostic variables	Predictive variables	N	Methodology	Localization of the markers	(Refs.)	
Tissue proteins	αSMA/ACTA2	Tashireva et al, 2017	αSMA (CD68, RS1,FAP)	Upregulated	NA	NA	Positive	Luminal B HER2+	NA	NA	36	RT-PCR	Stroma	(77)	
		Yamashita et al, 2012	αSMA	Upregulated	Positive	NS	NS	NS	Shorter OS	NA	60	IHC	Stroma	(44)	
		Fernandez-Nogueira et al, 2020	αSMA (FGF5, FGFR2, c-Src)	Upregulated	NA	NA	NA	HER2+	Shorter OS	High risk of reccurence after trastuzumab	64	IHC	Stroma	(28)	
		Vathiotis et al, 2021	αSMA	Upregulated	NA	NA	NA	HER2+	Shorter DFS	Resistance to trastuzumab	151	GeoMx	Stroma	(45)	
		Kim et al,2019	αSMA	Upregulated	NA	NA	NA	ER+	Shorter RFS	NA	209	Online data (GSE2034)	Tumour + Stroma	(42)	
		Hu et al, 2018	αSM (FSP-1, PDPN)	Upregulated	Positive	NS	Positive	ER-	Shorter DFS	NA	3,680	Meta-analysis	Stroma	(47)	
		Wang et al, 2016	αSMA (THBS1, TNC, FN, SPARC)	Upregulated	NA	NA	NA	NA	Shorter OS, DFS	NA	100	IHC	Stroma	(43)	
		Busch et al, 2012	αSMA (pERK)	Upregulated	NA	NA	NA	NA	shorter DFS	NS	922	IHC	Stroma	(46)	
		Yazhou et al, 2004	αSMA (CD34)	Upregulated	Positive	NS	Positive	NA	NA	NA	58	IHC	Stroma	(48)	
	S100A4/FSP-1	Park et al, 2016	S100A4/FSP-1 (FAP, PDGFRα, PDGFRβ, NG2, PDPN)	Down-regulated	NS	NS	Positive	ER-	Shorter DFS	NA	628	IHC	Stroma	(54)	
	
		Hu et al, 2018	S100A4/FSP-1 (αSMA, PDPN)	Upregulated	NS	NS	NS	NS	Shorter OS	NA	3,680	Meta-analysis	Stroma	(47)	
		de Silva Rudland et al, 2006	S100A4/FSP-1 (osteoponin)	Upregulated	NS	NS	NS	NS	Shorter OS	NA	312	IHC	Stroma	(55)	
		Li et al, 2015	S100A4/FSP-1	Upregulated	NA	NA	NA	NA	NA	Higher CR	65	IHC	Stroma	(57)	
		Pedersen et al, 2002	S100A4/FSP-1	Upregulated	Positive	NS	NS	ER-	NS	NA	66	IHC	Stroma	(56)	
		McKiernan et al, 2011	S100A4/FSP-1 (S100A1, S100A2, S100A6, S100A8, S100A9, S100A10, S100A11, S100A14)	Upregulated	NS	NS	NS	Basal subtype	NS	NA	295	IHC	Stroma	(58)	
	PDGFRβ	Hu et al, 2021	PDGFRβ	Upregulated	NA	NA	NA	NA	Shorter OS, DFS	NA	1,455	Meta-analysis	Stroma	(66)	
		Paulsson et al, 2009	PDGFRβ	Upregulated	Positive	Positive	NS	ER-, PR-, HER2+	Shorter RFS	NA	512	IHC	Stroma	(64)	
		Paulsson et al, 2017	PDGFRβ	Down-regulated	NS	Negative	NS	NS	NA	Longer RFS after tamoxifen treatment	564	IHC	Stroma	(65)	
	PDPN	Park et al, 2016	PDPN (S100A4/FSP-1, FAP, PDGFRα, PDGFRβ, NG2)	Upregulated	NS	NS	Positive	ER-	Shorter DFS	NA	628	IHC	Stroma	(54)	
		Hu et al, 2018	PDPN (S100A4/FSP-1, αSMA)	Upregulated	NS	NS	NS	NS	Shorter DFS	NA	3,680	Meta-analysis	Stroma	(47)	
		Schoppmann et al, 2012	PDPN	Upregulated	Positive	NS	NS	ER-	Shorter OS,DFS	NA	367	IHC	Stroma	(70)	
		Niemiec et al, 2018	PDPN	Upregulated	NS	Positive	Positive	NS	Shorter DFS	NA	203	IHC	Stroma	(69)	
		Tanaka et al, 2020	PDPN	Upregulated	NS	NS	NA	PR-	Shorter DFS, DSS	NA	169	IHC	Stroma	(71)	
		Pula et al, 2011	PDPN	Upregulated	Positive	Positive	Positive	ER-	Shorter OS	NA	117	IHC	Stroma	(72)	
		Friedman et al, 2020	PDPN (S100A4)	Upregulated	NA	NA	NA	NA	Shorter DFS	NA	12	IHC	Stroma	(52)	
		Pula et al, 2013	PDPN	Upregulated	Positive	Positive	NS	NS	NS	NA	257	IHC	Stroma	(73)	
	FAP	Tashireva et al, 2017	FAP (αSMA, CD68, RS1)	Upregulated	NA	NA	NA	NA	Presence of distant metastases	NA	36	RT-PCR	Stroma	(77)	
		Bonneau et al, 2020	FAP (CD29, αSMA, PDGFRβ, FSP-1)	Upregulated	NA	NA	NA	NA	Decreased RFS	NA	52	IHC	Stroma	(79)	
		Ariga et al, 2001	FAP	Upregulated	NA	NA	NA	NA	Longer OS, DFS	NA	112	IHC	Stroma	(78)	
	TGF-β1	Liu et al, 2022 (survivin)	TGF-β1	Upregulated	NS	NS	NS	TNBC	Shorter OS, PFS	NA	142	ELISA	Stroma	(84)	
		Koumoundourou et al, 2007	TGF-β1 (pSmad 2/3)	Down-regulated	NS	NS	NA	PR-	Presence of distant metastases	NA	61	IHC	Stroma	(83)	
	HDGF	Chen et al, 2012	HDGF	Upregulated	Positive	NA	Positive	NS	Shorter RFS	NA	86	IHC	Stroma	(87)	
		Qiu et al,2021	HDGF	Upregulated	NA	NA	NA	NA	Shorter DFS	NA	1,111	online data (TCGA)	Tumour+ Stroma	(88)	
	PDGF	Seymour et al, 1993	PDGF- AA, PDGFR- BB	Upregulated	NS	NS	NS	NA	Shorter OS	Lower CR	37	IHC, ELISA	Stroma	(92)	
		Jansson et al, 2018	PDGF-CC (PDGFRα PDGFRβ)	Upregulated	Positive	Positive	Positive	TNBC	Shorter DFS	NA	489	IHC	Stroma	(91)	
	Cytokines	Yao et al, 2016	CCL2	Upregulated	NS	Negative	NS	HER2-	Shorter DFS	NA	427	IHC	Stroma	(97)	
		Heiskala et al, 2019	CCL2 (CD14)	Upregulated	Positive	NS	Positive	NA	Shorter RFS	NA	137	IHC	Stroma	(98)	
		Yaal-Hahoshen et al, 2006	CCL5	Upregulated	NA	NA	NA	NA	Shorter RFS	NA	142	IHC	Stroma	(100)	
		Yamaguchi et al, 2021	CCL5 (CCR3, CCRR1, CCR5)	Upregulated	positive	NS	NS	HER2-, ER-.PR-	Shorter RFS	NA	111	IHC	Stroma	(99)	
	HH	Arnold et al, 2017	HH (Wnt)	Upregulated	NS	NS	NS	TNBC	Shorter RFS,OS	NA	36	IHC	Stroma	(102)	
	FGF	Surowiak et al, 2007	FGF2 (bFGF) (Ki-67, VEGF)	Upregulated	NS	Negative	Negative	NS	Shorter OS, RFS	NA	45	IHC	Stroma	(107)	
		Yiangou et al, 1997	FGF2	Upregulated	NS	NS	NS	NS	Longer OS, DFS	NA	51	RT-PCR and IHC	Stroma	(108)	
		Faridi et al, 2002	FGF2	Upregulated	Positive	NS	NS	NS	NS	NA	111	IHC	Stroma	(110)	
		Shee et al, 2018	FGF2	Upregulated	NA	NA	NA	Luminal	Shorter OS,RFS	Tamoxifen resistance	2,054	IHC	Stroma	(34)	
		Granato et al, 2004	FGF2 (VEGF)	Upregulated	NS	NS	NS	NS	NA	NA	62	IHC	Stroma	(109)	
		Colomer et al, 1997	FGF2	Down-regulated	NS	Negative	NS	NS	Shorter OS, RFS	NA	140	ELISA	Cytosol	(105)	
		Linderholm et al, 2003	FGF2 (VEGF)	Upregulated	NS	Negative	Negative	NS	Longer OS, RFS	NS	1,307	ELISA	Cytosol	(106)	
		Smith et al, 1999	FGF2	Upregulated	Negative	Negative	NS	ER+	NS	NA	149	ELISA	Cytosol	(111)	
		Fernandez-Nogueira et al, 2020	FGF5 (αSMA, FGFR2, c-Src)	Upregulated Down-regulated	NA	NA	NA	NA	Shorter OS, RFS
NA	NA
Higher pCR	64	IHC	Stroma	(28)	
		Meijer et al, 2008	FGF17 (FGFR1-4)	Upregulated	Negative	NS	Negative	NA	NA	NS	285	RT-PCR	Stroma	(112)	
	Circulating proteins	Ao et al, 2015	αSMA, FAP	Upregulated	NA	NA	NA	NA	Positive correlation with distant metastasis	NA	47	CTC	Serum	(41)	
		Al-Ashkar et al, 2020	αSMA	Upregulated	Positive	NS	NS	NS	Increased risk of metastasis	NA	46	ELISA	Serum	(119)	
		Seymour et al, 1993	PDGF	Upregulated	NS	NS	NS	NA	Shorter OS	Lower CR	37	ELISA	Serum	(92)	
		El-Abd et al, 2008	S100A4/FSP-1	Upregulated	NS	NS	Positive	NS	Shorter	NA	100	RT-PCR	Serum	(114)	
		Zhu et al, 2020	PDPN	Upregulated	Positive	NA	NA	NA	Presence of distant metastases	NA	159	CTC	Serum	(116)	
		Cai et al, 2023	TGF-β1 (MMP-9)	Upregulated	Positive	NS	Positive	TNBC	Shorter DFS	NA	86	ELISA	Serum	(118)	
		Panis et al, 2013	TGF-β1	Down-regulated	NA	NA	NA	TNBC	Presence of distant metastases	NS	101	ELISA	Serum	(121)	
		Ivanović et al, 2005	TGF-β1	Upregulated	NS	NS	NS	NS	Shorter OS, presence of distant metastases	NA	53	ELISA	Serum	(113)	
		Tripsianis et al, 2013	TGF-β1 (IL-6, TNF-α)	Upregulated	NS	NS	Positive	HER2	Shorter OS	NA	130	ELISA	Serum	(115)	
		Paccagnella et al, 2022	TGF-β1, IL-4, IL-6, IL-8, IL-10, CCL-2, CCL-4 (analysed as cluster)	Down regulated	NA	NA	NA	NA	Shorter OS	Shorter OS after 4 courses of eribulin	41	Ella Simple Plex system	Serum	(124)	
		Wang et al, 2020	CXCL8	Down-regulated	NS	NS	NS	NS	NA	higher pCR rate	303	ELISA	Serum	(123)	
		Kjaer et al, 2020	EGF	Down-regulated	NA	NA	NA	NA	NS	NA	311	ELISA	Serum	(126)	
		Seymour et al, 1993	PDGF	Upregulated	NS	NS	NS	NA	Shorter OS	Lower CR	37	ELISA	Serum	(92)	
		El-Abd et al, 2008	S100A4/FSP-1	Upregulated	NS	NS	Positive	NS	Shorter	NA	100	RT-PCR	Serum	(114)	
		Zhu et al, 2020	PDPN	Upregulated	Positive	NA	NA	NA	Presence of distant metastases	NA	159	CTC	Serum	(116)	
		Cai et al, 2023	TGF-β1 (MMP-9)	Upregulated	Positive	NS	Positive	TNBC	Shorter DFS	NA	86	ELISA	Serum	(118)	
		Panis et al, 2013	TGF-β1	Down-regulated	NA	NA	NA	TNBC	Presence of distant metastases	NS	101	ELISA	Serum	(121)	
		Ivanović et al, 2005	TGF-β1	Upregulated	NS	NS	NS	NS	Shorter OS, presence of distant metastases	NA	53	ELISA	Serum	(113)	
		Tripsianis et al, 2013	TGF-β1 (IL-6, TNF-α)	Upregulated	NS	NS	Positive	HER2	Shorter OS	NA	130	ELISA	Serum	(115)	
		Paccagnella et al, 2022	TGF-β1, IL-4, IL-6, IL-8, IL-10, CCL-2, CCL-4 (analysed as cluster)	Down regulated	NA	NA	NA	NA	Shorter OS	Shorter OS after 4 courses of eribulin	41	Ella Simple Plex system	Serum	(124)	
		Wang et al, 2020	CXCL8	Down-regulated	NS	NS	NS	NS	NA	higher pCR rate	303	ELISA	Serum	(123)	
		Kjaer et al, 2020	EGF	Down-regulated	NA	NA	NA	NA	NS	NA	311	ELISA	Serum	(126)	
		Tripsianis et al, 2013	IL-6 (TNF-α)	Upregulated	NS	NS	Positive	HER2+ ER+	Shorter OS	NA	112	ELISA	Serum	(117)	
		Tripsianis et al, 2013	IL-6 (TGF-β1, TNF-α)	Upregulated	NS	NS	Positive	HER2	Shorter OS	NA	130	ELISA	Serum	(115)	
		Yahia et al, 2023	IL-6	Down-regulated	NS	NA	Negative	NS	NA	NA	70	ELISA	Serum	(120)	
		Milanović et al, 2018	IL-6 (IL-8)	Upregulated	NA	NA	NA	HER2+	Longer OS	NA	79	ELISA	Serum	(122)	
		Granato et al, 2003	FGF2	Upregulated	NS	NS	NS	NS	NA	NA	62	ELISA	Serum	(109)	
In brackets are given markers additionally analysed in the study. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; FGF, fibroblast growth factor; TGF-β, tumour growth factor β; HH, sonic hedgehog; IL-6, interleukin 6; α-SMA, smooth muscle actin α; FAP, fibroblast activating protein; FSP/S100A4, fibroblast specific protein; PDGF, platelet-derived growth factor; PDGFRβ, PDGF receptor β; PDPN, podoplanin; HDGF, heparin binding growth factor; CXCL, chemokine (C-X-C motif) ligand; CCL, C-C motif chemokine ligand; EFG, epidermal growth factor; OS, overall survival; DFS, disease-free survival; RFS,recurrence free survival; N, cohort size; IHC, immunohistochemistry; RT-PCR, reverse transcription PCR.
==== Refs
References

1 Santolla MF Maggiolini M The FGF/FGFR system in breast cancer: Oncogenic features and therapeutic perspectives Cancers (Basel) 12 3029 2020 10.3390/cancers12103029 33081025
2 Servetto A Formisano L Arteaga CL FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors Biochim Biophys Acta Rev Cancer 1876 188595 2021 10.1016/j.bbcan.2021.188595 34303787
3 Braun M Piasecka D Tomasik B Mieczkowski K Stawiski K Zielinska A Kopczynski J Nejc D Kordek R Sadej R Romanska HM Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma Cancers (Basel) 12 2713 2020 10.3390/cancers12092713 32971804
4 Mieczkowski K Kitowska K Braun M Galikowska-Bogut B Gorska-Arcisz M Piasecka D Stawiski K Zaczek AJ Nejc D Kordek R FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer Mol Oncol 16 2823 2842 2022 10.1002/1878-0261.13274 35726195
5 Meric-Bernstam F Bahleda R Hierro C Sanson M Bridgewater J Arkenau HT Tran B Kelley RK Park JO Javle M Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: A phase I dose-expansion study Cancer Discov 12 402 415 2022 10.1158/2159-8290.CD-21-0697 34551969
6 Coombes RC Badman PD Lozano-Kuehne JP Liu X Macpherson IR Zubairi I Baird RD Rosenfeld N Garcia-Corbacho J Cresti N Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer Nat Commun 13 3246 2022 10.1038/s41467-022-30666-0 35688802
7 De Luca A Frezzetti D Gallo M Normanno N FGFR-targeted therapeutics for the treatment of breast cancer Expert Opin Investig Drugs 26 303 311 2017 10.1080/13543784.2017.1287173 28121208
8 Chew NJ Lim Kam Sian TCC Nguyen EV Shin SY Yang J Hui MN Deng N McLean CA Welm AL Lim E Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models Breast Cancer Res 23 82 2021 10.1186/s13058-021-01461-4 34344433
9 Ronnov-Jessen L Petersen OW Koteliansky VE Bissell MJ The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells J Clin Invest 95 859 873 1995 10.1172/JCI117736 7532191
10 Elenbaas B Weinberg RA Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation Exp Cell Res 264 169 184 2001 10.1006/excr.2000.5133 11237532
11 Erez N Truitt M Olson P Arron ST Hanahan D Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner Cancer Cell 17 135 147 2010 10.1016/j.ccr.2009.12.041 20138012
12 Tejada ML Yu L Dong J Jung K Meng G Peale FV Frantz GD Hall L Liang X Gerber HP Ferrara N Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma Clin Cancer Res 12 2676 2688 2006 10.1158/1078-0432.CCR-05-1770 16675559
13 Tian H Callahan CA DuPree KJ Darbonne WC Ahn CP Scales SJ de Sauvage FJ Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis Proc Natl Acad Sci USA 106 4254 4259 2009 10.1073/pnas.0813203106 19246386
14 Aggarwal V Tuli HS Varol A Thakral F Yerer MB Sak K Varol M Jain A Khan MA Sethi G Role of reactive oxygen species in cancer progression: Molecular mechanisms and recent advancements Biomolecules 9 735 2019 10.3390/biom9110735 31766246
15 Direkze NC Hodivala-Dilke K Jeffery R Hunt T Poulsom R Oukrif D Alison MR Wright NA Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts Cancer Res 64 8492 8495 2004 10.1158/0008-5472.CAN-04-1708 15574751
16 Kidd S Spaeth E Watson K Burks J Lu H Klopp A Andreeff M Marini FC Origins of the tumor microenvironment: Quantitative assessment of adipose-derived and bone marrow-derived stroma PLoS One 7 e30563 2012 10.1371/journal.pone.0030563 22363446
17 Abe R Donnelly SC Peng T Bucala R Metz CN Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites J Immunol 166 7556 7562 2001 10.4049/jimmunol.166.12.7556 11390511
18 Zeisberg EM Potenta S Xie L Zeisberg M Kalluri R Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts Cancer Res 67 10123 10128 2007 10.1158/0008-5472.CAN-07-3127 17974953
19 Timperi E Gueguen P Molgora M Magagna I Kieffer Y Lopez-Lastra S Sirven P Baudrin LG Baulande S Nicolas A Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer Cancer Res 82 3291 3306 2022 10.1158/0008-5472.CAN-22-1427 35862581
20 Nurmik M Ullmann P Rodriguez F Haan S Letellier E In search of definitions: Cancer-associated fibroblasts and their markers Int J Cancer 146 895 905 2020 10.1002/ijc.32193 30734283
21 Chen X Song E Turning foes to friends: Targeting cancer-associated fibroblasts Nat Rev Drug Discov 18 99 115 2019 10.1038/s41573-018-0004-1 30470818
22 Costa A Kieffer Y Scholer-Dahirel A Pelon F Bourachot B Cardon M Sirven P Magagna I Fuhrmann L Bernard C Fibroblast heterogeneity and immunosuppressive environment in human breast cancer Cancer Cell 33 463 479.e410 2018 10.1016/j.ccell.2018.01.011 29455927
23 Glabman RA Choyke PL Sato N Cancer-associated fibroblasts: Tumorigenicity and targeting for cancer therapy Cancers (Basel) 14 3906 2022 10.3390/cancers14163906 36010899
24 Paulsson J Micke P Prognostic relevance of cancer-associated fibroblasts in human cancer Semin Cancer Biol 25 61 68 2014 10.1016/j.semcancer.2014.02.006 24560651
25 Marchini C Montani M Konstantinidou G Orrù R Mannucci S Ramadori G Gabrielli F Baruzzi A Berton G Merigo F Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies PLoS One 5 e14131 2010 10.1371/journal.pone.0014131 21152434
26 Frings O Augsten M Tobin NP Carlson J Paulsson J Pena C Olsson E Veerla S Bergh J Ostman A Sonnhammer EL Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling Am J Pathol 182 2037 2047 2013 10.1016/j.ajpath.2013.02.018 23583284
27 Lappano R Rigiracciolo DC Belfiore A Maggiolini M De Francesco EM Cancer associated fibroblasts: Role in breast cancer and potential as therapeutic targets Expert Opin Ther Targets 24 559 572 2020 10.1080/14728222.2020.1751819 32249708
28 Fernández-Nogueira P Mancino M Fuster G López-Plana A Jauregui P Almendro V Enreig E Menéndez S Rojo F Noguera-Castells A Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation Clin Cancer Res 26 1432 1448 2020 10.1158/1078-0432.CCR-19-0353 31699826
29 Palmieri C Roberts-Clark D Assadi-Sabet A Coope RC O'Hare M Sunters A Hanby A Slade MJ Gomm JJ Lam EW Coombes RC Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cells J Endocrinol 177 65 81 2003 10.1677/joe.0.1770065 12697038
30 Kalluri R The biology and function of fibroblasts in cancer Nat Rev Cancer 16 582 598 2016 10.1038/nrc.2016.73 27550820
31 Cerliani JP Guillardoy T Giulianelli S Vaque JP Gutkind JS Vanzulli SI Martins R Zeitlin E Lamb CA Lanari C Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer Cancer Res 71 3720 3731 2011 10.1158/0008-5472.CAN-10-3074 21464042
32 Mao Y Keller ET Garfield DH Shen K Wang J Stromal cells in tumor microenvironment and breast cancer Cancer Metastasis Rev 32 303 315 2013 10.1007/s10555-012-9415-3 23114846
33 Louault K Li RR DeClerck YA Cancer-associated fibroblasts: Understanding their heterogeneity Cancers (Basel) 12 3108 2020 10.3390/cancers12113108 33114328
34 Shee K Yang W Hinds JW Hampsch RA Varn FS Traphagen NA Patel K Cheng C Jenkins NP Kettenbach AN Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer J Exp Med 215 895 910 2018 10.1084/jem.20171818 29436393
35 Clayton NS Wilson AS Laurent EP Grose RP Carter EP Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment Dev Dyn 246 493 501 2017 10.1002/dvdy.24514 28470714
36 Zhou Z Wu B Tang X Ke R Zou Q Comprehensive analysis of fibroblast growth factor receptor (FGFR) family genes in breast cancer by integrating online databases and bioinformatics Med Sci Monit 26 e923517 2020 10.12659/MSM.923517 32381997
37 Suh J Kim DH Lee YH Jang JH Surh YJ Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling Mol Carcinog 59 1028 1040 2020 10.1002/mc.23233 32557854
38 Xie Y Su N Yang J Tan Q Huang S Jin M Ni Z Zhang B Zhang D Luo F FGF/FGFR signaling in health and disease Signal Transduct Target Ther 5 181 2020 10.1038/s41392-020-00222-7 32879300
39 Otranto M Sarrazy V Bonte F Hinz B Gabbiani G Desmouliere A The role of the myofibroblast in tumor stroma remodeling Cell Adh Migr 6 203 219 2012 10.4161/cam.20377 22568985
40 Chakrabarti R Lee M Higgs HN Multiple roles for actin in secretory and endocytic pathways Curr Biol 31 R603 R618 2021 10.1016/j.cub.2021.03.038 34033793
41 Ao Z Shah SH Machlin LM Parajuli R Miller PC Rawal S Williams AJ Cote RJ Lippman ME Datar RH El-Ashry D Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer Cancer Res 75 4681 4687 2015 10.1158/0008-5472.CAN-15-1633 26471358
42 Kim S You D Jeong Y Yu J Kim SW Nam SJ Lee JE TP53 upregulates α-smooth muscle actin expression in tamoxifen-resistant breast cancer cells Oncol Rep 41 1075 1082 2019 30535478
43 Wang T Srivastava S Hartman M Buhari SA Chan CW Iau P Khin LW Wong A Tan SH Goh BC Lee SC High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer Oncotarget 7 55155 55168 2016 10.18632/oncotarget.10894 27487140
44 Yamashita M Ogawa T Zhang X Hanamura N Kashikura Y Takamura M Yoneda M Shiraishi T Role of stromal myofibroblasts in invasive breast cancer: Stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome Breast Cancer 19 170 176 2012 10.1007/s12282-010-0234-5 20978953
45 Vathiotis IA Moutafi MK Divakar P Aung TN Qing T Fernandez A Yaghoobi V El-Abed S Wang Y Guillaume S Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer Clin Cancer Res 27 6156 6163 2021 10.1158/1078-0432.CCR-21-2103 34465600
46 Busch S Rydén L Stål O Jirström K Landberg G Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer PLoS One 7 e45669 2012 10.1371/journal.pone.0045669 23029174
47 Hu G Wang S Xu F Ding Q Chen W Zhong K Huang L Xu Q Tumor-infiltrating podoplanin+ fibroblasts predict worse outcome in solid tumors Cell Physiol Biochem 51 1041 1050 2018 10.1159/000495484 30476924
48 Yazhou C Wenlv S Weidong Z Licun W Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast Tumour Biol 25 290 295 2004 10.1159/000081394 15627894
49 Bresnick AR Weber DJ Zimmer DB S100 proteins in cancer Nat Rev Cancer 15 96 109 2015 10.1038/nrc3893 25614008
50 D'Ambrosi N Milani M Apolloni S S100A4 in the physiology and pathology of the central and peripheral nervous system Cells 10 798 2021 10.3390/cells10040798 33918416
51 Liu S Zhang H Li Y Zhang Y Bian Y Zeng Y Yao X Wan J Chen X Li J S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation J Immunother Cancer 9 e002548 2021 10.1136/jitc-2021-002548 34145030
52 Friedman G Levi-Galibov O David E Bornstein C Giladi A Dadiani M Mayo A Halperin C Pevsner-Fischer M Lavon H Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs clinical outcome Nat Cancer 1 692 708 2020 10.1038/s43018-020-0082-y 35122040
53 Grum-Schwensen B Klingelhofer J Berg CH El-Naaman C Grigorian M Lukanidin E Ambartsumian N Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene Cancer Res 65 3772 3780 2005 10.1158/0008-5472.CAN-04-4510 15867373
54 Park CK Jung WH Koo JS Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma Breast Cancer Res Treat 159 55 69 2016 10.1007/s10549-016-3929-2 27469595
55 de Silva Rudland S Martin L Roshanlall C Winstanley J Leinster S Platt-Higgins A Carroll J West C Barraclough R Rudland P Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer Clin Cancer Res 12 1192 1200 2006 10.1158/1078-0432.CCR-05-1580 16489073
56 Pedersen KB Nesland JM Fodstad O Maelandsmo GM Expression of S100A4, E-cadherin, alphaand beta-catenin in breast cancer biopsies Br J Cancer 87 1281 1286 2002 10.1038/sj.bjc.6600624 12439718
57 Li WL Zhang Y Liu BG Du Q Zhou CX Tian XS Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer Exp Ther Med 10 1983 1989 2015 10.3892/etm.2015.2743 26640584
58 McKiernan E McDermott EW Evoy D Crown J Duffy MJ The role of S100 genes in breast cancer progression Tumour Biol 32 441 450 2011 10.1007/s13277-010-0137-2 21153724
59 Park SY Kim HM Koo JS Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer Breast Cancer Res Treat 149 727 741 2015 10.1007/s10549-015-3291-9 25667103
60 Donovan J Shiwen X Norman J Abraham D Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts Fibrogenesis Tissue Repair 6 10 2013 10.1186/1755-1536-6-10 23663505
61 Claesson-Welsh L Ronnstrand L Heldin CH Biosynthesis and intracellular transport of the receptor for platelet-derived growth factor Proc Natl Acad Sci USA 84 8796 8800 1987 10.1073/pnas.84.24.8796 2827155
62 Lavie D Ben-Shmuel A Erez N Scherz-Shouval R Cancer-associated fibroblasts in the single-cell era Nat Cancer 3 793 807 2022 10.1038/s43018-022-00411-z 35883004
63 Pietras K Pahler J Bergers G Hanahan D Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting PLoS Med 5 e19 2008 10.1371/journal.pmed.0050019 18232728
64 Paulsson J Sjöblom T Micke P Pontén F Landberg G Heldin CH Bergh J Brennan DJ Jirström K Ostman A Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer Am J Pathol 175 334 341 2009 10.2353/ajpath.2009.081030 19498003
65 Paulsson J Rydén L Strell C Frings O Tobin NP Fornander T Bergh J Landberg G Stål O Östman A High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer J Pathol Clin Res 3 38 43 2017 10.1002/cjp2.56 28138400
66 Hu G Huang L Zhong K Meng L Xu F Wang S Zhang T PDGFR-β+ fibroblasts deteriorate survival in human solid tumors: a meta-analysis Aging (Albany NY) 13 13693 13707 2021 10.18632/aging.202952 33946048
67 Yam C Murthy RK Rauch GM Murray JL Walters RS Valero V Brewster AM Bast RC Jr Booser DJ Giordano SH A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-b Invest New Drugs 36 1103 1109 2018 10.1007/s10637-018-0672-z 30311036
68 Wicki A Lehembre F Wick N Hantusch B Kerjaschki D Christofori G Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton Cancer Cell 9 261 272 2006 10.1016/j.ccr.2006.03.010 16616332
69 Niemiec J Adamczyk A Harazin-Lechowska A Ambicka A Grela-Wojewoda A Majchrzyk K Kruczak A Sas-Korczyńska B Ryś J Podoplanin-positive cancer-associated stromal fibroblasts in primary tumor and synchronous lymph node metastases of HER2-overexpressing breast carcinomas Anticancer Res 38 1957 1965 2018 29599311
70 Schoppmann SF Berghoff A Dinhof C Jakesz R Gnant M Dubsky P Jesch B Heinzl H Birner P Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer Breast Cancer Res Treat 134 237 244 2012 10.1007/s10549-012-1984-x 22350732
71 Tanaka Y Ohno T Kadonaga T Kidokoro Y Wakahara M Nosaka K Sakabe T Suzuki Y Nakamura H Umekita Y Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2-negative subtype Breast Cancer 28 822 828 2021 10.1007/s12282-021-01217-0 33481184
72 Pula B Jethon A Piotrowska A Gomulkiewicz A Owczarek T Calik J Wojnar A Witkiewicz W Rys J and Ugorski M Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma Histopathology 59 1249 1260 2011 10.1111/j.1365-2559.2011.04060.x 22175904
73 Pula B Wojnar A Werynska B Ambicka A Kruczak A Witkiewicz W Ugorski M Podhorska-Okolow M Dziegiel P Impact of different tumour stroma assessment methods regarding podoplanin expression on clinical outcome in patients with invasive ductal breast carcinoma Anticancer Res 33 1447 1455 2013 23564785
74 Liu R Li H Liu L Yu J Ren X Fibroblast activation protein: A potential therapeutic target in cancer Cancer Biol Ther 13 123 129 2012 10.4161/cbt.13.3.18696 22236832
75 Sarkar M Nguyen T Gundre E Ogunlusi O El-Sobky M Giri B Sarkar TR Cancer-associated fibroblasts: The chief architect in the tumor microenvironment Front Cell Dev Biol 11 1089068 2023 10.3389/fcell.2023.1089068 36793444
76 Lo A Wang LCS Scholler J Monslow J Avery D Newick K O'Brien S Evans RA Bajor DJ Clendenin C Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells Cancer Res 75 2800 2810 2015 10.1158/0008-5472.CAN-14-3041 25979873
77 Tashireva LA Denisov EV Gerashchenko TS Pautova DN Bulda kov MA Zavyalova MV Kzhysh kowska J Cherdyntseva NV Perelmuter VM Intratumoral heterogeneity of macrophages and fibroblasts in breast cancer is associated with the morphological diversity of tumor cells and contributes to lymph node metastasis Immunobiology 222 631 640 2017 10.1016/j.imbio.2016.11.012 27916281
78 Ariga N Sato E Ohuchi N Nagura H Ohtani H Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast Int J Cancer 95 67 72 2001 10.1002/1097-0215(20010120)95:1<67::AID-IJC1012>3.0.CO;2-U 11241314
79 Bonneau C Eliès A Kieffer Y Bourachot B Ladoire S Pelon F Hequet D Guinebretière JM Blanchet C Vincent-Salomon A A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer Breast Cancer Res 22 76 2020 10.1186/s13058-020-01311-9 32665033
80 Biernacka A Dobaczewski M Frangogiannis NG TGF-β signaling in fibrosis Growth Factors 29 196 202 2011 10.3109/08977194.2011.595714 21740331
81 Shi X Young CD Zhou H Wang X Transforming growth factor-β signaling in fibrotic diseases and cancer-associated fibroblasts Biomolecules 10 1666 2020 10.3390/biom10121666 33322749
82 Casey TM Eneman J Crocker A White J Tessitore J Stanley M Harlow S Bunn JY Weaver D Muss H Plaut K Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta 1) increase invasion rate of tumor cells: A population study Breast Cancer Res Treat 110 39 49 2008 10.1007/s10549-007-9684-7 17674196
83 Koumoundourou D Kassimatis T Zolota V Tzorakoeleftherakis E Ravazoula P Vassiliou V Kardamakis D Varakis J Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2,N0 tumours Anticancer Res 27 2613 2620 2007 17695423
84 Liu N Qi D Jiang J Zhang J Yu C Significance of combined TGF-β1 and survivin expression on the prognosis of patients with triple-negative breast cancer Oncol Lett 23 193 2022 10.3892/ol.2022.13313 35527782
85 Nakamura H Kambe H Egawa T Kimura Y Ito H Hayashi E Yamamoto H Sato J Kishimoto S Partial purification and characterization of human hepatoma-derived growth factor Clin Chim Acta 183 273 284 1989 10.1016/0009-8981(89)90361-6 2553304
86 Enomoto H Nakamura H Liu W Nishiguchi S Hepatoma-derived growth factor: Its possible involvement in the progression of hepatocellular carcinoma Int J Mol Sci 16 14086 14097 2015 10.3390/ijms160614086 26101867
87 Chen X Yun J Fei F Yi J Tian R Li S Gan X Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer Pathol Res Pract 208 437 443 2012 10.1016/j.prp.2012.03.004 22682760
88 Qiu L Ma Y Chen X Zhou L Zhang H Zhong G Zhang L Tang J Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway J Transl Med 19 344 2021 10.1186/s12967-021-03021-y 34376200
89 Anderberg C Pietras K On the origin of cancer-associated fibroblasts Cell Cycle 8 1461 1462 2009 10.4161/cc.8.10.8557 19395855
90 Kuzet SE Gaggioli C Fibroblast activation in cancer: When seed fertilizes soil Cell Tissue Res 365 607 619 2016 10.1007/s00441-016-2467-x 27474009
91 Jansson S Aaltonen K Bendahl PO Falck AK Karlsson M Pietras K Rydén L The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence Breast Cancer Res Treat 169 231 241 2018 10.1007/s10549-018-4664-7 29380207
92 Seymour L Dajee D Bezwoda WR Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer Breast Cancer Res Treat 26 247 252 1993 10.1007/BF00665802 8251649
93 Liubomirski Y Lerrer S Meshel T Rubinstein-Achiasaf L Morein D Wiemann S Körner C Ben-Baruch A Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative breast cancer Front Immunol 10 757 2019 10.3389/fimmu.2019.00757 31031757
94 Lin S Sun L Lyu X Ai X Du D Su N Li H Zhang L Yu J Yuan S Lactate-activated macrophages induced aerobic glycolysis and epithelial-mesenchymal transition in breast cancer by regulation of CCL5-CCR5 axis: A positive metabolic feedback loop Oncotarget 8 110426 110443 2017 10.18632/oncotarget.22786 29299159
95 Qian BZ Li J Zhang H Kitamura T Zhang J Campion LR Kaiser EA Snyder LA Pollard JW CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis Nature 475 222 225 2011 10.1038/nature10138 21654748
96 Zhou B Sun C Li N Shan W Lu H Guo L Guo E Xia M Weng D Meng L Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways Int J Oncol 48 2087 2097 2016 10.3892/ijo.2016.3442 26983899
97 Yao M Yu E Staggs V Fan F Cheng N Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers Mod Pathol 29 810 823 2016 10.1038/modpathol.2016.78 27125354
98 Heiskala M Leidenius M Joensuu K Heikkilä P High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer Virchows Arch 474 3 12 2019 10.1007/s00428-018-2461-7 30368555
99 Yamaguchi M Takagi K Narita K Miki Y Onodera Y Miyashita M Sasano H Suzuki T Stromal CCL5 promotes breast cancer progression by interacting with CCR3 in tumor cells Int J Mol Sci 22 1918 2021 10.3390/ijms22041918 33671956
100 Yaal-Hahoshen N Shina S Leider-Trejo L Barnea I Shabtai EL Azenshtein E Greenberg I Keydar I Ben-Baruch A The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients Clin Cancer Res 12 4474 4480 2006 10.1158/1078-0432.CCR-06-0074 16899591
101 Liu S Dontu G Mantle ID Patel S Ahn NS Jackson KW Suri P Wicha MS Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells Cancer Res 66 6063 6071 2006 10.1158/0008-5472.CAN-06-0054 16778178
102 Arnold KM Pohlig RT Sims-Mourtada J Co-activation of Hedgehog and Wnt signaling pathways is associated with poor outcomes in triple negative breast cancer Oncol Lett 14 5285 5292 2017 29142600
103 Beenken A Mohammadi M The FGF family: Biology, pathophysiology and therapy Nat Rev Drug Discov 8 235 253 2009 10.1038/nrd2792 19247306
104 Babina IS Turner NC Advances and challenges in targeting FGFR signalling in cancer Nat Rev Cancer 17 318 332 2017 10.1038/nrc.2017.8 28303906
105 Colomer R Aparicio J Montero S Guzmán C Larrodera L Cortés-Funes H Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma Br J Cancer 76 1215 1220 1997 10.1038/bjc.1997.536 9365172
106 Linderholm BK Lindh B Beckman L Erlanson M Edin K Travelin B Bergh J Grankvist K Henriksson R Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers Clin Breast Cancer 4 340 347 2003 10.3816/CBC.2003.n.039 14715109
107 Surowiak P Murawa D Materna V Maciejczyk A Pudelko M Ciesla S Breborowicz J Murawa P Zabel M Dietel M Lage H Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor Anticancer Res 27 2917 2924 2007 17695471
108 Yiangou C Gomm JJ Coope RC Law M Luqmani YA Shousha S Coombes RC Johnston CL Fibroblast growth factor 2 in breast cancer: Occurrence and prognostic significance Br J Cancer 75 28 33 1997 10.1038/bjc.1997.5 9000594
109 Granato AM Nanni O Falcini F Folli S Mosconi G De Paola F Medri L Amadori D Volpi A Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: Useful as diagnostic tools? Breast Cancer Res 6 R38 R45 2004 10.1186/bcr745 14680499
110 Faridi A Rudlowski C Biesterfeld S Schuh S Rath W Schröder W Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer Pathol Res Pract 198 1 5 2002 10.1078/0344-0338-00176 11866204
111 Smith K Fox SB Whitehouse R Taylor M Greenall M Clarke J Harris AL Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival Ann Oncol 10 707 713 1999 10.1023/A:1008303614441 10442194
112 Meijer D Sieuwerts AM Look MP van Agthoven T Foekens JA Dorssers LCJ Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer Endocr Relat Cancer 15 101 111 2008 10.1677/ERC-07-0080 18310279
113 Ivanović V Demajo M Krtolica K Krajnović M Konstantinović M Baltić V Prtenjak G Stojiljković B Breberina M Nesković-Konstantinović Z Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients Clin Chim Acta 371 191 193 2006 10.1016/j.cca.2006.02.027 16650397
114 El-Abd E El-Tahan R Fahmy L Zaki S Faid W Sobhi A Kandil K El-Kwisky F Serum metastasin mRNA is an important survival predictor in breast cancer Br J Biomed Sci 65 90 94 2008 10.1080/09674845.2008.11732804 19055112
115 Tripsianis G Papadopoulou E Romanidis K Katotomichelakis M Anagnostopoulos K Kontomanolis E Botaitis S Tentes I Kortsaris A Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF-α and TGF-b1 Asian Pac J Cancer Prev 14 6813 6820 2013 10.7314/APJCP.2013.14.11.6813 24377611
116 Zhu X Xu M Zhao X Shen F Ruan C Zhao Y The detection of plasma soluble podoplanin of patients with breast cancer and its clinical signification Cancer Manag Res 12 13207 13214 2020 10.2147/CMAR.S281785 33380828
117 Tripsianis G Papadopoulou E Anagnostopoulos K Botaitis S Katotomichelakis M Romanidis K Kontomanolis E Tentes I Kortsaris A Coexpression of IL-6 and TNF-α: Prognostic significance on breast cancer outcome Neoplasma 61 205 212 2014 10.4149/neo_2014_026 24299316
118 Cai S Zheng J Song H Wu H Cai W Relationship between serum TGF-β 1, MMP-9 and IL-1β and pathological features and prognosis in breast cancer Front Genet 13 1095338 2023 10.3389/fgene.2022.1095338 36712861
119 Al-Ashkar N Zetoune AB S100A14 serum level and its correlation with prognostic factors in breast cancer J Egypt Natl Canc Inst 32 37 2020 10.1186/s43046-020-00048-y 32984913
120 Yahia S Tahari Z Medjdoub A Tahari FZ Bessaih N Messatfa M Deblaoui F Raiah M Ouldcadi H Seddiki S Sahraoui T Expression profile of interleukin-6, 4-hydroxy-2-nonenal, and hypoxia-inducible factor 1-α in women with breast cancer and their association with clinicopathological parameters Contemp Oncol (Pozn) 27 14 21 2023 37266334
121 Panis C Herrera AC Victorino VJ Aranome AM Cecchini R Screening of circulating TGF-β levels and its clinicopathological significance in human breast cancer Anticancer Res 33 737 742 2013 23393376
122 Milovanović J Todorović-Raković N Radulovic M Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer Cytokine 118 93 98 2019 10.1016/j.cyto.2018.02.019 29482885
123 Wang RX Ji P Gong Y Shao ZM Chen S Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: A retrospective pilot study Breast Cancer Res Treat 181 561 570 2020 10.1007/s10549-020-05660-z 32361849
124 Paccagnella M Abbona A Michelotti A Geuna E Ruatta F Landucci E Denaro N Vanella P Lo Nigro C Galizia D Circulating cytokines in metastatic breast cancer patients select different prognostic groups and patients who might benefit from treatment beyond progression Vaccines (Basel) 10 78 2022 10.3390/vaccines10010078 35062739
125 Denys H Derycke L Hendrix A Westbroek W Gheldof A Narine K Pauwels P Gespach C Bracke M De Wever O Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion Cancer Lett 266 263 274 2008 10.1016/j.canlet.2008.02.068 18423981
126 Kjær IM Olsen DA Brandslund I Bechmann T Jakobsen EH Bogh SB Madsen JS Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer Sci Rep 10 16558 2020 10.1038/s41598-020-72944-1 33024132
